Veronesi A, Galligioni E, Lo Re G, Sorio R, Saracchini S, Francini M, Merlo A, Dal Bo V, Monfardini S
Eur J Cancer Clin Oncol. 1986 Dec;22(12):1457-60. doi: 10.1016/0277-5379(86)90079-9.
From October 1981 to October 1984, 42 consecutive patients with locally advanced unresectable or metastatic transitional cell carcinoma of the urinary tract were treated with cis-Platinum 50 mg/m2 i.v. and Adriamycin 50 mg/m2 i.v. day 1, and Fluorouracil 500 mg/m2 i.v. and VM26 100 mg/m2 days 1 and 8, every 3 weeks. In the 36 evaluable patients, 4 complete remissions and 15 partial remissions were noted (52.7% response rate). Of the 12 patients with previously untreated, locally advanced bladder carcinoma, 8 responded, with 3 pathologically confirmed complete remissions. Toxicity was moderate. Median survival was 44 weeks. This 4-drug combination had significant palliative activity in our patient population. Its role in the preoperative setting deserves further evaluation.
1981年10月至1984年10月，连续42例局部晚期无法切除或转移性泌尿道移行细胞癌患者接受如下治疗：第1天静脉注射顺铂50mg/m²和阿霉素50mg/m²，第1天和第8天静脉注射氟尿嘧啶500mg/m²和VM26 100mg/m²，每3周重复。在36例可评估患者中，观察到4例完全缓解和15例部分缓解（缓解率52.7%）。在12例先前未接受治疗的局部晚期膀胱癌患者中，8例有反应，其中3例经病理证实为完全缓解。毒性为中度。中位生存期为44周。这种四联药物组合在我们的患者群体中具有显著的姑息治疗活性。其在术前治疗中的作用值得进一步评估。
